Rapid Response of Palmoplantar Psoriasis to Risankizumab: A Case Report

Rapid Response of Palmoplantar Psoriasis to Risankizumab: A Case Report

Abdullah Muqrin Al Muqrin,1 Abdulaziz A Alghamdi,1 Ziad M AlShaalan2 1Dermatology, Prince Mohammed Medical City, Skaka, AlJouf, Saudi Arabia; 2Department of Internal Medicine, College of Medicine, Jouf University, Skakak, AlJouf, Saudi ArabiaCorrespondence: Abdullah Muqrin Al Muqrin, Dermatology, Pr...

Full description

Bibliographic Details
Main Authors:	Al Muqrin AM, Alghamdi AA, AlShaalan ZM
Format:	Article
Language:	English
Published:	Dove Medical Press 2022-10-01
Series:	Clinical, Cosmetic and Investigational Dermatology
Subjects:	psoriasis risankizumab palmoplantar rapid onset biologic biological agent.
Online Access:	https://www.dovepress.com/rapid-response-of-palmoplantar-psoriasis-to-risankizumab-a-case-report-peer-reviewed-fulltext-article-CCID

Similar Items

Risankizumab for the Treatment of Palmoplantar Pustular Psoriasis: A Report of Two Cases
by: Luigi Gargiulo, et al.
Published: (2023-04-01)

Erythrodermic Psoriasis Managed with Risankizumab
by: Abdulmajeed Alajlan, et al.
Published: (2022-08-01)

Rapidly and successful improvement of nail psoriasis with risankizumab
by: Diego Orsini, et al.
Published: (2023-10-01)

Use of risankizumab in two HIV-positive patients with psoriasis
by: Khalad Maliyar, MD, BA, et al.
Published: (2023-03-01)

Risankizumab: an anti-IL-23 antibody for the treatment of psoriasis
by: Haugh IM, et al.
Published: (2018-11-01)

Risankizumab in the treatment of psoriasis – literature review
by: Katarzyna Banaszczyk
Published: (2019-06-01)

Long-Term Efficacy and Safety of Risankizumab for Moderate to Severe Psoriasis: A 2-Year Real-Life Retrospective Study
by: Matteo Megna, et al.
Published: (2023-04-01)

A Case of Erythrodermic Psoriasis Successfully Treated with Risankizumab
by: Megna M, et al.
Published: (2023-12-01)

Mycosis fungoides diagnosed after exposure to risankizumab for psoriasis
by: Lauren M. Fahmy, BS, et al.
Published: (2023-11-01)

Effectiveness of risankizumab in the treatment of palmoplantar psoriasis: a 52-week Italian real-life experience
by: Giacomo Caldarola, et al.
Published: (2023-01-01)

Efficacy and safety of treatment of moderate and severe psoriasis with the interleukin 23 inhibitor risankizumab
by: Andrey L. Bakulev, et al.
Published: (2022-09-01)

A Case of Recalcitrant Circinate Generalized (Lapière) Psoriasis Successfully Treated with Risankizumab
by: Angelo Ruggiero, et al.
Published: (2022-05-01)

Spotlight on risankizumab and its potential in the treatment of plaque psoriasis: evidence to date
by: Machado Á, et al.
Published: (2018-11-01)

Successful treatment of psoriasis with risankizumab in a patient with telangiectasia macularis eruptiva perstans
by: Cara Barber, MD, MPH, et al.
Published: (2022-06-01)

Efficacy and safety of risankizumab for moderate-to-severe plaque psoriasis in clinical practice: A 16-week Canadian retrospective multicenter cohort study
by: Yuliya Lytvyn, PhD, et al.
Published: (2022-03-01)

Effectiveness, Tolerability, and Drug Survival of Risankizumab in a Real-World Setting: A Three-Year Retrospective Multicenter Study—IL PSO (ITALIAN LANDSCAPE PSORIASIS)
by: Luigi Gargiulo, et al.
Published: (2024-01-01)

Anti-IL-23 and anti-IL-17 drugs for the treatment of non-pustular palmoplantar psoriasis: a real-life retrospective study
by: Luciano Ibba, et al.
Published: (2023-12-01)

Risankizumab for Plaque and Guttate Psoriasis in a Patient With IgA-Related Glomerulonephritis
by: Annunziata Dattola, et al.
Published: (2021-10-01)

Guselkumab, tildrakizumab, and risankizumab in a real-world setting: drug survival and effectiveness in the treatment of psoriasis and psoriatic arthritis
by: Cathrine Dawn Büttner Elgaard, et al.
Published: (2023-12-01)

Dermoscopy in the diagnosis of palmoplantar eczema and palmoplantar psoriasis: A cross-sectional, comparative study from a tertiary care centre in North India
by: Payal Chauhan, et al.
Published: (2023-01-01)

A severe psoriasis flare after COVID-19 treated with risankizumab: complete skin clearance after 16 weeks
by: Luciano Ibba, et al.
Published: (2023-06-01)

Real-life Effectiveness and Safety of Risankizumab in Moderate-to-severe Plaque Psoriasis: A 40-week Multicentric Retrospective Study
by: Riccardo G. Borroni, et al.
Published: (2021-11-01)

Risankizumab Therapy for Moderate-to-Severe Psoriasis—A Multi-Center, Long-Term, Real-Life Study from Poland
by: Michał Adamczyk, et al.
Published: (2023-02-01)

Black Cumin Oil: A New Treatment for Palmoplantar Psoriasis.
by: Naseer A. Al-Harchan
Published: (2010-07-01)

An economic evaluation of risankizumab versus other biologic treatments of moderate to severe plaque psoriasis in Japan
by: Hidehisa Saeki, et al.
Published: (2022-01-01)

Risankizumab for the Treatment of Moderate to Severe Psoriasis: Impact on Health-Related Quality of Life and Psychological Wellbeing
by: Gracia-Cazaña T, et al.
Published: (2023-01-01)

New possibilities of systemic therapy of plaque psoriasis with the IL23p19 inhibitor risankizumab
by: O. V. Zhukova, et al.
Published: (2021-06-01)

Risankizumab: Daily Practice Experience of High Need Patients
by: Alexandra M. G. Brunasso, et al.
Published: (2023-06-01)

Real-world effectiveness and safety of risankizumab in patients with plaque psoriasis in whom guselkumab failed recently: A multicenter retrospective study of switching within the interleukin-23 inhibitor class
by: Ahmed Bagit, BSc, et al.
Published: (2023-09-01)

Efficacy and Safety of Risankizumab in Hidradenitis Suppurativa: A Case Series
by: Federica Repetto, et al.
Published: (2022-09-01)

Commentary: Successful treatment of refractory palmoplantar pustular psoriasis with apremilast: a case series
by: Madison Hackley, et al.
Published: (2023-10-01)

Risankizumab for the Treatment of the Patients with Moderate to Severe Plaque Psoriasis During a 24-Week Period: Real-Life Experience
by: Gönülal M, et al.
Published: (2023-12-01)

Efficacy, safety, usability, and acceptability of risankizumab 150 mg formulation administered by prefilled syringe or by an autoinjector for moderate to severe plaque psoriasis
by: Andrew Blauvelt, et al.
Published: (2022-05-01)

Evaluation of topical 0.1% tazarotene cream in the treatment of palmoplantar psoriasis: An observer-blinded randomized controlled study
by: Bijal H Mehta, et al.
Published: (2011-01-01)

Combination biologic therapy for the treatment of severe palmoplantar pustulosis
by: Kristin M. Torre, BS, et al.
Published: (2017-05-01)

Switching to risankizumab from ustekinumab or adalimumab in plaque psoriasis patients improves PASI and DLQI outcomes for sub-optimal responders
by: Bruce Strober, et al.
Published: (2022-10-01)

Effectiveness of risankizumab in plaque psoriasis with involvement of difficult-to-treat areas: a real-world experience from two referral centers
by: Diego Orsini, et al.
Published: (2023-12-01)

Pharmacovigilance of Risankizumab in the Treatment of Psoriasis and Arthritic Psoriasis: Real-World Data from EudraVigilance Database
by: Fabrizio Calapai, et al.
Published: (2023-07-01)

Cost per responder for risankizumab vs secukinumab in patients with moderate-to-severe plaque psoriasis in Italy
by: Paolo Gisondi, et al.
Published: (2021-09-01)

Successful treatment of palmoplantar psoriasis with chemical peeling and gentian violet
by: Jeffrey A. Bubley, MD, et al.
Published: (2021-11-01)